Oculis to Present at Upcoming March Investor Conference

Rhea-AI Summary

Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC), a global biopharmaceutical company focused on eye care and sight preservation, has announced its participation in the upcoming Leerink Global Healthcare Conference.

The company's Chief Financial Officer, Sylvia Cheung, will present on March 11, 2025, at 3:00pm ET in Miami Beach, FL. Investors can request one-on-one meetings through their institutional representatives.

A live webcast of the fireside chat will be accessible through the Events and Presentations section of the Oculis website under Investors & Media.

News Market Reaction – OCS

+5.50%

+5.50% Session move

In the trading session that priced this news, OCS gained 5.50%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ZUG, Switzerland, March 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Oculis will be attending and presenting at the following upcoming investor conference:

Leerink Global Healthcare Conference
Presenter: Sylvia Cheung, Chief Financial Officer
Presentation date and time: March 11, 2025 at 3:00pm ET
Location: Miami Beach, FL

The Company will be available for one-on-one meetings during the conference. Interested investors should contact their respective representative at the sponsoring institution to request meetings.

A live webcast of the fireside chat can also be accessed by visiting the Oculis website on the Events and Presentations section under Investors & Media.

About Oculis

Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) purposefully driven to save sight and improve eye care. Oculis’ highly differentiated pipeline of multiple innovative product candidates in development includes: OCS-01, a topical eye drop candidate for diabetic macular edema; Privosegtor (OCS-05), a neuroprotective candidate for acute optic neuritis with potentially broad clinical applications in other neuro-ophthalmic diseases and Licaminlimab (OCS-02), a topical biologic anti-TNFα eye drop candidate for dry eye disease. Headquartered in Switzerland with operations in the U.S. and Iceland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.

For more information, please visit: www.oculis.com

Oculis Contacts
Ms. Sylvia Cheung, CFO
sylvia.cheung@oculis.com

Investor & Media Relations
LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com

FAQ

When is Oculis (OCS) presenting at the Leerink Global Healthcare Conference 2025?

Oculis will present on March 11, 2025, at 3:00pm ET in Miami Beach, FL.

Who will represent Oculis (OCS) at the Leerink Global Healthcare Conference?

Sylvia Cheung, Chief Financial Officer of Oculis, will present at the conference.

How can investors access Oculis (OCS) presentation at the Leerink Conference?

Investors can watch the live webcast through the Events and Presentations section on Oculis' website under Investors & Media.

How can investors schedule meetings with Oculis (OCS) management at the Leerink Conference?

Investors should contact their representatives at the sponsoring institution to request one-on-one meetings.